Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for atherosclerosis inflammation in patients with cancer receiving immune checkpoint therapy
NL-OMON58638Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in atherosclerosis, sponsored by Amsterdam University Medical Center. Started Aug 2026; status: recruiting.
02
Drugs
colchicine
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NL-OMON58638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58638.